Professional Documents
Culture Documents
Ranbaxy was incorporated in 1961 and went public in 1973. For the year
2008, the Company recorded Global Sales of US $ 1,682 Mn, reflecting a growth
of 4%. The Company has a balanced mix of revenues from emerging and
developed markets that contribute 54% and 39% respectively. In 2008, North
America, the Company’s largest market contributed sales of US $ 449 Mn,
followed by Europe garnering US $ 330 Mn. Business in Asia has been going
strong with India clocking sales of around US $ 300 Mn with market leadership in
several business segments, backed by strong brand-building skills.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese
innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and
generic pharmaceutical powerhouse. The combined entity now ranks among the
top 15 pharmaceutical companies, globally. The transformational deal will place
Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its
global reach and in its capabilities in drug development and manufacturing.
Company profile
Ranbaxy Laboratories Ltd. is the largest pharmaceutical company in India
and one of the world’s top 100 pharmaceutical companies. Ranbaxy is
specialist in the preparation of generic drugs; Ranbaxy is also one of the
world top 10 in that pharmaceutical category as well, with India's
agreement to apply international patent law at the beginning of 2005,
Ranbaxy has begun converting itself into a full-fledged research-based
1
pharmaceutical company. A major part of this effort has been the
establishment of the company's own research and development center,
which has enabled the company to begin to enter the new chemical entities
NCE) and novel drug delivery systems (NDDS) markets.
Ranbaxy Laboratories Limited has excelled in its endeavor in drug research and
manufacture, providing quality products not only at par with global markets but
also facilitating the same.
2
Ranbaxy are committed to provide quality generics at affordable prices to the
patients worldwide with a view to help bring down the healthcare costs.
Companies grow from strength to strength in the global generic space in the years
to come. While the company continues to enhance the momentum of generics
business in over 125 markets, they are also accelerating drug discovery program
through collaborations and alliances.
Company Strategies
For the year 2009, Ranbaxy has a clear strategy to harness its growth potential in
emerging markets, rebuild the US business through a series of actions on products
and facilities; actualize significant revenue upsides through First-to-File and Day-
1 launches strengthen the product / therapeutic pipeline and look for M&A
opportunities, complementing our geographic and therapeutic basket. Our focus
will be to resolve regulatory compliance issues and continue to strengthen cGMP
across all locations. Besides this, Ranbaxy and Daiichi Sankyo will identify key
projects to realize synergies at both the front and back ends of the business,
although, there will be much to contend with, considering that the industry is
projected to grow at around 5% in 2009.
Ranbaxy is focused on increasing the momentum in the generics business in its key markets
through organic and inorganic growth routes. The Company continues to evaluate acquisition
opportunities in India, emerging and developed markets to strengthen its business and
competitiveness. Growth is well spread across geographies with focus on emerging markets.
Ranbaxy has forayed into new specialty therapeutic segments like Bio-similars, Oncology,
Peptides and Limuses. These new growth areas will add significant depth to the existing product
pipeline.
Company Growth
Consolidated net sales at Rs. 18,884 Mn, a growth of 14% (USD 431 Mn).
Emerging markets portfolio achieves sales of Rs. 10,644 Mn, with a strong
growth of 20%; accounts for 56% of sales (USD 243 Mn).
3
Developed markets sales grew by 9% to Rs. 7,089 Mn (USD 162 Mn);
accounts for 38% of sales.
Earnings before Interest, Tax, Depreciation & Amortization (EBITDA) for
the quarter are Rs. 1,440 Mn (8%). EBITDA for the year to date is Rs. 7,253
Mn reflecting a margin to sales of 14%.
Gross margin on year to date basis maintained at 51% despite adverse
economic conditions this year.
Over the current year there has been a consistent improvement in Working
Capital management with a result that the Company’s Gross Working
Capital has reduced by 5%.
Competitors
The pharmaceutical industry is characterized by rapid advances in scientific
knowledge and ability to discover new drugs. The industry is therefore led by large
manufacturers and marketers of drugs investing heavily in research &development,
having clinical testing, marketing and distributing capabilities. Some of the main
competitors of Ranbaxy are:
4
Marketing Management
Introduction
Dr. Marshall says “What we have is more strategic. Now it says marketing is
really something that makes the organization run."
In Ranbaxy
Ranbaxy has set itself apart in the marketplace through the rapid expansion of its
product line and its willingness to emulate complex drug formulations. Ranbaxy
commitment to quickly expanding the breadth and depth of its product line has
been a key to its success in the marketplace.
5
analgesics.
Ranbaxy has a turnkey marketing group that works with other pharmaceutical
companies to co-market and co-promote a variety of chemicals and products. As a
marketing partner, Ranbaxy is able to meet the marketing needs of companies
while they themselves focus their efforts on a drug's development, manufacturing,
distribution and sales.
Marketing Strategies
One of the key tasks for the department is to identify opportunities in different
markets and distribution channels and pursue those to developing and establish
new relationships in the marketplace. Managed Care and Internet marketing is
couple of key areas that the department is looking to introduce into its ever-
expanding service offerings.
Introduction
HRM is the management function that helps the mangers to recruit, select,
train and develop the organizational members for the purpose of achieving the
stated organizational goals.
6
continuous staff functions which is challenging.
In Ranbaxy
Many Indian companies that perform well in domestic markets have not yet
expanded to the International arena. Several factors such as lack of confidence,
lack of technical know how and perhaps lack of resources inhibit leading Indian
groups to expand their area of activities to other parts of the world. HRM can play
a crucial role in changing the attitude of the company and its employees in order to
facilitate entry and presence in the foreign markets. This is effectively illustrated in
7
the case of the Indian pharmaceutical giant RANBAXY which succeeded in
expanding its business internationally due to the single-handed determination of its
past CEO, Dr. Parvinder Singh, and the manner in which he managed to change the
mindset of his employees
Ranbaxy inched upwards because the employees shared their CEO's belief and
dream that they were in a position to harness their resources and capabilities and to
be successful in foreign markets. Together they developed continual cross border
learning programs to enrich their ways of working and functioning. Furthermore,
they invited managers from other parts of the world to be present on their board.
This step enabled them to catalyze their globalization process. Moreover, the CEO
firmly led the company to integrate backwards, to enter new markets and to
develop novel drugs. This provided with the edge to succeed in the global
marketplace.
Experienced and capable people joined the organisation, promising talent within
the Company was put through a planned development programme called LEAD.
These initiatives are designed to further strengthen our core operations and position
the Company on a stronger footing while experienced and capable people joined
the organisation, promising talent within the Company was put through a planned
development.
8
Life at Ranbaxy
A
career
at
Opportunities
The global spread of Ranbaxy and the blazing growth in business provides ample
opportunities for employees to build careers in various fields. Opportunities have
never been a constraint for the deserving. The company believes in employee
growth that goes beyond vertical movements and change in designations. Potential
and performance are the pillars of career progression at Ranbaxy. A robust
development process supports this. Managers will generally have the opportunity
to live and work in different countries; such international experience will help
them better understand our complex business and grow both personally and
professionally.
Salaries and other benefits in Ranbaxy are comparable with the best in the industry
and one can expect to be rewarded highly if the performance is consistently
outstanding.
Group Life Insurance, Medical Insurance and Pension plans are a few examples of
the benefits we provide to our employees and their dependents with adequate
financial protection on long term basis.
9
Stock ownership
Environment
10
audit, by a leading external verifying agency both manufacturing facilities
conformed to all audit specifications and continued to remain ISO14001 complaint.
Notable progress was made towards achieving the defined environmental
objectives, programs and long-term goals. For further improving the wastewater
management, an Agitated Thin Film Dryer and Plate type Ultra Filtration were
added as incremental safeguards, at the Toansa API facility.
Health
Company always strives to make a meaningful impact on the quality of their lives
by bringing preventive, promotive and curative healthcare services to their
doorstep. Nearly three decades ago in 1979, Ranbaxy started its health care
initiatives in certain identified rural areas of Punjab. As the reach of the program
grew, the Ranbaxy Community Health Care Society (RCHS) was established in
1994. A novel idea of providing mobile health care outreach service for the poor
and underprivileged was initiated. The program today benefits nearly 2 lakh people
in 77 rural and urban slum areas in Punjab, Haryana, Himachal Pradesh, Madhya
Pradesh and Delhi. Today, six well equipped mobile health care vans with teams of
medics and paramedics are actively engaged in the delivery of health care to our
target population in these states. The issues addressed include maternal-child
health, family planning, reproductive health, adolescent health, health education
and AIDS awareness.
Safety
It is constant endeavour to scale up and better safety practices. A number of
initiatives were undertaken to enhance workplace safety. The emergency
preparedness was ensured through regular tabletop exercises and mock drills at all
our manufacturing facilities and R&D centres. At Toansa manufacturing facility,
the 'Fire and Safety Risk Assessment' and the 'Hazardous Area Classification' was
reviewed by third party specialists. The National Safety Council also conducted
external safety audits at Toansa and Mohali. A crossfunctional team of Corporate
EHS, Engineering and Facility professionals along with an external specialist
further undertook external safety audits at the Corporate Office. Extensive safety
11
training programs were also conducted by internal and external specialists at all
manufacturing facilities, including those managed by contract.
The three basic financial statements viz. the balance sheet. the profit and loss
account and the statement of changes in financial position are playing a significant
role and most, management uses the information carried in these statement is used
12
by most, management, creditors, Investors and Debtors to evaluate about the past
performance and current position in order to predict future performance and
position of the firm
Management
Investors
Investors are concerned with the safety of their investment and the ability of
the company to earn profit and in turn the dividend they earn on their investment.
The Investor forms their own opinion as to the soundness of increasing in a
company. One way the investor from their opinion of the company’s earning
capacity is by computing earning per share.
Creditors
The long-term creditors are not only interested in company's ability to repay
but also in the ability of the company to realize profit on the capital employed.
13
A creditor will be interested in ascertaining whether the company can
employ the funds loaned to it in such a way that it will able to meet current interest
obligation and repay the loan when it falls due. If a company earn less than what is
paid in the form of interest, it is not safe to lend money to the company.
Labours
Labour has an interest in the operating results and the financial strength of a
company. The remuneration of the worker must be generated from the company
revenues: Thus, the workers' wages, to a great extent, depend up on the success of
the firm. Frequently, labour unions use the information presented in the financial
statement as a basic for their demand for increase in wages. The past operating
performance of the firm, as well as its current financial position, is often studied to
measure the ability of the Firm to meet new wage commitments.
14
B) Functional classification or classification according to test:
In view of the financial management or according to the tests satisfied, various
Ratios have been classified as below:
Liquidity Ratios:
These are the Ratios which measure the short term solvency or financial
position of a firm. These Ratios are calculated to comment up on the short term
paying capacity of a concern or the firm’s ability to meet its current obligations.
The various liquidity Ratios are current Ratio, liquidity Ratio and absolute liquid
Ratio. Further to see the efficiency with which the liquid resources have been
employed by a firm, debtor’s turnover and creditor’s turnover Ratios are
calculated.
Long term solvency Ratios conveys a firm’s ability to meet the interest costs
and repayments schedules of its long term obligations e.g.: debt equity Ratio and
Interest coverage Ratio and leverage Ratio.
Activity Ratios:
Activity Ratios are calculated to measure the efficiency with which assets
are being turned over into sales, e.g.; Debtors turnover Ratio.
Profitability Ratios:
These Ratios measure the result of business operations or overall
performance and effectiveness of the firm, e.g.; Gross profit Ratio, operating Ratio
or return on capital employed.
The various profitability Ratios have been given in the chart exhibiting the
classifications of Ratios according to test. Generally, profitability Ratios is
calculated. 1) In relation to sales, and 2) in relation to investments.
15
The Ratios have also been classified according to the significance or
importance. Some Ratios are more important than others and the firm may classify
then as primary and secondary Ratios.
The British Institute of management has recommended the classification
Ratios according to importance for inter-firm comparisons. For inter-firm
comparisons the Ratio may be classified as primary Ratios and secondary Ratios.
The primary Ratio is one, which is of the prime importance to a concern; Return on
capital employed is named as primary Ratio. The other Ratios e.g. the relationship
of operating profit to sales or the relationship of sales to total assets of the firm.
Interpretation
16
sales turnover
2008
2007
2005
2004
amount
2) Current ratio
Interpretation
In the above table, Current Ratio of the company for five years is depicted.
Current ratio=current assets/current liabilities
The Ideal Current Ratio is 2:1
If the company has ideal current ratio then it is assumed that its current
assets are sufficient to meet its current liabilities or its working capital is
adequate.
17
current ratio
1.4
1.2
1
0.8
ratio
current ratio
0.6
0.4
0.2
0
2004 2005 2006 2007 2008
year
3) Quick ratio
Interpretation
In the above table, Quick Ratio of the company for five years is
depicted
Quick ratio = liquid assets / current liabilities.
The Ideal Quick Ratio is assumed 1:1.
The higher of the ratio shows the better ability of the company to
discharge its short term liabilities
18
When required ratio provides more stringent test of short term
solvency because liquid assets are more liquid than the current liabilities
Quick ratio
1.05
0.95
0.85
0.8
0.75
2004 2005 2006 2007 2008
4) Debt–Equity ratio
Interpretation
19
The lower debt-Equity ratio expresses that there is greater claim of the
share holders over the assets of the company which is considered good
from the point of view of the company.
1.6
1.4
1.2
1
ratio
Interpretation
20
Inventory turnover Ratio indicates the efficiency of the firm in producing
and selling its product. Or the inventory/ stock turnover indicates the
efficiency of the firms inventory management.
From the above analysis of the stock turnover ratio, stock Turnover
to the business is less comparing to the previous year turn over
turnover of RLL the present scenario is better utilization of stock in
to business.
4.5
4.4
4.3
4.2
ratio
Interpretation
21
From the above analysis of Gross Profit ratio, gross profit ratio is
less compared to the previous year
If the gross profit ratio is declining that may put the management in
difficulty
18
16
14
12
10
ratio
Interpretation
In the above table, Net profit margin of the company for five
years is depicted
Net Profit Ratio=Net Profit/Net sales*100
The Net profit ratio reveals the operational efficiency and in
efficiency of the management of business
22
From the above analysis of Net Profit ratio, net profit ratio is less
compared to the previous years
Since net profit ratio is declining that shows the inefficiency of
management
20
15
10
5
0
ratio
Interpretation
23
EPS is calculated by dividing the Earnings after Income
Tax (EAIT), which is available to Equity Share Holders, with the
Number of Equity Shares. EPS is used to measure the Profit to Equity
Share Holders on ‘Per’ Share Basis.
The year 2008 has the least EPS -24.85& 2004 has the
highest EPS 28.38
40
30
20
10
ratio
-30
year
Conclusion
24
Rs. 7,702 Mn was recognized during the year basis the fair value
measurement principle suggested in the Standard.
Suggestions
The company has incurred loss in current fiscal year; company has to
make future plans in such a way that it is not repeated.
The company has expanded globally but the company should take care of
the domestic market also.
Declaration
25
I hereby declare that this company analysis report of RANBAXY submitted
by me to the department of business administration is a bonafide work undertaken
by me and it is not submitted to any other university or institution by any other
person for the award of any degree diploma /certificate or published any time
before.
Place:
Date: Name
(S.ROHIT MITRA)
(08311E0025)
Acknowledgement
26
I would like to express my gratitude to my guide Mr. Coca
Satyanaraya faculty in business management of SREENIDHI
INSTITUTE OF TECHNOLOGY AND SCIENCE for his
cooperation and valuable suggestion during the study
process. I also want to thank my HOD Dr.Y.Satyanarayana
for extending his help during my analysis.
27